...
机译:AML和MDS和MDS和新治疗方案中氮杂硝乙汀化疗抗性的机制
Charles Univ Prague Fac Med 1 BIOCEV Vestec Czech Republic;
Univ Florida Dept Med Div Hematol Oncol Gainesville FL USA;
Cell Works Grp Inc San Jose CA USA;
Charles Univ Prague Fac Med 1 Pathophysiol Prague Czech Republic;
Charles Univ Prague Fac Med 1 BIOCEV Vestec Czech Republic;
Gen Hosp Med Dept Hematol 21 Prague Czech Republic;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cellworks Res India Private Ltd Bangalore Karnataka India;
Cell Works Grp Inc San Jose CA USA;
Univ Florida Gainesville FL USA;
Gen Hosp Med Dept Hematol 21 Prague Czech Republic;
机译:AML和MDS和MDS和新治疗方案中氮杂硝乙汀化疗抗性的机制
机译:多中心,开放标签,3臂研究Gilteritinib,Gilteritinib加氮杂氨酸,或仅在新诊断的FLT3突变(FLT3(MUT +))急性髓性白血病(AML)患者中没有资格对强化诱导化疗的患者:从安全队列中发现
机译:IDO在MDS / AML疾病的进展及其在抗氮杂氨酸的作用:潜在的新药物目标?
机译:克服胰腺癌的治疗抗性不是PDT和化学疗法的简单组合:在3D肿瘤模型中评估PDT-化学疗法的组合
机译:同源盒基因HOXA7与急性髓细胞白血病(AML)的化疗耐药性。
机译:由LAMP2缺乏引起的阿扎胞苷耐药性:在MDS / AML患者中使用自噬抑制剂的治疗窗口?
机译:在常规化疗后可能会发生克隆血液血液血液,并且与NQO1途径的加速端粒缩短和缺陷相关;可能的机制导致T-AML / MDS的风险增加